New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Subscribe now to continue reading.

“As the first therapy with a novel mechanism of action to be approved for CIDP patients in more than 30 years, this approval is an extremely important step towards addressing the unmet needs of patients with this debilitating condition and further signals argenx’s commitment to bring innovative therapeutic options to Australian patients,” said Kathryn Evans, Australia General Manager for argenx. …

Subscribe now to continue reading.

New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Latest Video

Most Read

Rare genetic motor neurone disease treatment finally reaches Australian patients

Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this

Which is it? The two perspectives on patient input compounded by the lack of transparency

Melbourne oncologist takes the reins at Australia's private cancer physicians body

Taking a stake is not the same as spectating investor risk and expecting a benefit

New Stories

The 'Dispatched' Week in Review Podcast - 11 September

Rare genetic motor neurone disease treatment finally reaches Australian patients

NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms

AI Health Summit 2026

Taking a stake is not the same as spectating investor risk and expecting a benefit

Melbourne oncologist takes the reins at Australia's private cancer physicians body

Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this

Sign In

New treatment milestone offers fresh hope for Australians living with CIDP

This is a preview of subscriber content

Latest Video

Most Read

Rare genetic motor neurone disease treatment finally reaches Australian patients

Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this

Which is it? The two perspectives on patient input compounded by the lack of transparency

Melbourne oncologist takes the reins at Australia's private cancer physicians body

Taking a stake is not the same as spectating investor risk and expecting a benefit

Follow Us

New Stories

The 'Dispatched' Week in Review Podcast - 11 September

Rare genetic motor neurone disease treatment finally reaches Australian patients

NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms

AI Health Summit 2026

Taking a stake is not the same as spectating investor risk and expecting a benefit

Melbourne oncologist takes the reins at Australia's private cancer physicians body

Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this